Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1645 1646
This examiner grants 45% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17473401 | TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB | Final Rejection | Genentech, Inc. |
| 18096167 | PSEUDOTYPED VIRUSES CONFIGURED TO EXPRESS CAR IN T-CELLS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17595112 | FIBROBLAST GENERATED PATIENT-SPECIFIC VACCINES | Non-Final OA | Figene, LLC |
| 17414968 | BIFUNCTIONAL MOLECULE DIRECTED AGAINST HUMAN PD-1 | Final Rejection | OSE IMMUNOTHERAPEUTICS |
| 18010611 | SITE SPECIFIC NOTCH-ACTIVATING MOLECULE AND USES THEREOF | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 15734755 | ANTIGEN-BINDING MOLECULE SHOWING CHANGED HALF-LIFE IN CYTOPLASM | Final Rejection | CHUGAI SEIYAKU KABUSHIKI KAISHA |
| 18419527 | ANTIBODY THAT BINDS ERBB-2 AND ERBB-3 | Final Rejection | Merus N.V. |
| 17792268 | FORMULATIONS OF CD38 ANTIBODIES AND USES THEREOF | Non-Final OA | GENMAB A/S |
| 17628382 | AXL ANTIBODY-DRUG CONJUGATES FOR USE IN TREATING CANCER | Non-Final OA | GENMAB A/S |
| 18259042 | A PLATFORM TO OBTAIN MONOCLONAL ANTIBODIES DIRECTED AGAINST PROCESSED TUMOR-SPECIFIC ANTIGENS | Non-Final OA | MEDITERRANEA THERANOSTIC SRL |
| 16979396 | METHODS OF SELECTING T CELL LINE FOR ADOPTIVE CELLULAR THERAPY | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 18308587 | METHODS FOR TREATING INHERITED METABOLIC DISORDERS | Non-Final OA | BLUEROCK THERAPEUTICS LP |
| 17272792 | MUSK ACTIVATION | Non-Final OA | ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC) |
| 18166769 | PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND EGFR, NKG2D, AND CD16 | Non-Final OA | Dragonfly Therapeutics, Inc. |
| 18002016 | STABLE FORMULATION FOR RECOMBINANT ANTI-PD-1 MONOCLONAL ANTIBODY | Non-Final OA | SINOCELLTECH LTD |
| 18062921 | ONCOLYTIC VIRUS BOOSTS T CELL RESPONSE FOR EFFECTIVE TIL THERAPY | Non-Final OA | H. LEE MOFFITT CANCER AND RESEARCH INSTITUTE, INC. |
| 17998584 | NEW METHOD TO TREAT CUTANEOUS T-CELL LYMPHOMAS AND TFH DERIVED LYMPHOMAS | Final Rejection | INSTITUT JEAN PAOLI & IRENE CALMETTES |
| 18053996 | ANTI-VISTA ANTIBODIES AND USES THEREOF | Non-Final OA | Sensei Biotherapeutics, Inc. |
| 17801014 | Method for Identifying Functional Disease-Specific Regulatory T Cells | Non-Final OA | Institut Mutualiste Montsouris |
| 17775543 | DOSAGE REGIMEN FOR ANTI-EGFRVIII AGENTS | Final Rejection | AMGEN RESEARCH (MUNICH) GMBH |
| 17436981 | LIQUID COMPOSITION COMPRISING ANTIBODY OF HUMAN INTERLEUKIN-4 RECEPTOR ALPHA | Non-Final OA | SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. |
| 17290753 | HOMODIMER-TYPE BISPECIFIC ANTIBODY TARGETING CD19 AND CD3, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | AMPSOURCE BIOPHARMA SHANGHAI INC. |
| 17252379 | COMPOSITIONS AND METHODS FOR MODULATING MONOCYTE AND MACROPHAGE INFLAMMATORY PHENOTYPES AND IMMUNOTHERAPY USES THEREOF | Non-Final OA | Verseau Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy